Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

Afrezza is still on the market ... they offer for this aspect of our product.” "Inhaled insulin offers the possibility of a cost effective, significant improvement in lifestyle - ease-of ...

“The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus,” he added. Afrezza has been evaluated in over 70 ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin ...

She has prescribed Afrezza to her patients since it was granted FDA approval and available in the U.S. nearly a decade ago. It’s the only rapid-acting inhaled insulin on the market and can help ...

"Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide, is an exciting milestone for MannKind and our partner Cipla,” said Michael Castagna, PharmD, ...